<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hypertrophic cardiomyopathy: Morphologic variants and the pathophysiology of left ventricular outflow tract obstruction</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hypertrophic cardiomyopathy: Morphologic variants and the pathophysiology of left ventricular outflow tract obstruction</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hypertrophic cardiomyopathy: Morphologic variants and the pathophysiology of left ventricular outflow tract obstruction</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Maron, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William J McKenna, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 06, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hypertrophic cardiomyopathy (HCM) is a genetically determined heart muscle disease most often (60 to 70 percent) caused by mutations in one of several sarcomere genes which encode components of the contractile apparatus. (See  <a class="medical medical_review" href="/d/html/4956.html" rel="external">"Hypertrophic cardiomyopathy: Gene mutations and clinical genetic testing"</a>.)</p><p>HCM is characterized by left ventricular (LV) hypertrophy of various morphologies, with a wide array of clinical manifestations and hemodynamic abnormalities (<a class="graphic graphic_figure graphicRef58156" href="/d/graphic/58156.html" rel="external">figure 1</a>). Depending in part upon the site and extent of cardiac hypertrophy, patients with HCM can develop one or more of the following abnormalities:</p><p class="bulletIndent1"><span class="glyph">●</span>LV outflow obstruction (LVOT)</p><p class="bulletIndent1"><span class="glyph">●</span>Diastolic dysfunction</p><p class="bulletIndent1"><span class="glyph">●</span>Myocardial ischemia</p><p class="bulletIndent1"><span class="glyph">●</span>Mitral regurgitation</p><p></p><p>These structural and functional abnormalities can produce a variety of symptoms, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Fatigue</p><p class="bulletIndent1"><span class="glyph">●</span>Dyspnea</p><p class="bulletIndent1"><span class="glyph">●</span>Chest pain</p><p class="bulletIndent1"><span class="glyph">●</span>Palpitations</p><p class="bulletIndent1"><span class="glyph">●</span>Presyncope or syncope</p><p></p><p>In broad terms, the symptoms related to HCM can be categorized as those related to heart failure (HF), chest pain, or arrhythmias. Patients with HCM have an increased incidence of both supraventricular and ventricular arrhythmias and are at an increased risk for sudden cardiac death. (See  <a class="medical medical_review" href="/d/html/4926.html" rel="external">"Hypertrophic cardiomyopathy in adults: Supraventricular tachycardias including atrial fibrillation"</a> and  <a class="medical medical_review" href="/d/html/4952.html" rel="external">"Hypertrophic cardiomyopathy: Risk stratification for sudden cardiac death"</a>.)</p><p>A resting or exercise-provoked LVOT gradient is present in most patients with HCM (70 percent). Significant LVOT obstruction at rest, present in 20 to 30 percent, is an independent predictor of poor prognosis in patients with HCM. Four major approaches are available for treatment of LVOT obstruction in patients with HCM:</p><p class="bulletIndent1"><span class="glyph">●</span>Pharmacologic therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Septal myectomy</p><p class="bulletIndent1"><span class="glyph">●</span>Alcohol (ethanol) septal ablation</p><p class="bulletIndent1"><span class="glyph">●</span>Dual-chamber pacing (which has only a limited role)</p><p></p><p>This topic will review the pathophysiology of the LVOT obstruction in HCM as well as the morphologic variants of HCM. The clinical manifestations, diagnosis, evaluation, natural history, and treatment of this disorder are discussed separately. (See  <a class="medical medical_review" href="/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation"</a> and  <a class="medical medical_review" href="/d/html/4916.html" rel="external">"Hypertrophic cardiomyopathy: Natural history and prognosis"</a> and  <a class="medical medical_review" href="/d/html/4950.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients without outflow tract obstruction"</a> and  <a class="medical medical_review" href="/d/html/4920.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients with outflow tract obstruction"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">PATHOPHYSIOLOGY AND EVOLUTION OF LVOT OBSTRUCTION</span><span class="headingEndMark"> — </span>The identification of factors that contribute to the development of LVOT obstruction was initially facilitated by the advent of two-dimensional echocardiography. Subsequently, imaging findings from both echocardiography and cardiovascular magnetic resonance (CMR) imaging have been correlated with hemodynamic and cineangiographic findings. (See  <a class="medical medical_review" href="/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation", section on 'Cardiac catheterization'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Mechanism of LVOT obstruction</span><span class="headingEndMark"> — </span>Subaortic (ie, LVOT) obstruction in HCM is due to systolic anterior motion (SAM) of the mitral valve contacting the ventricular septum in midsystole (<a class="graphic graphic_movie graphicRef79426" href="/d/graphic/79426.html" rel="external">movie 1</a>). This creates mechanical impedance to blood flow as it exits the heart, resulting in a pressure gradient between the LV cavity and the aorta. Increased LV systolic pressures are recorded just below the level of the mitral valve leaflet-septal coaptation, while the systolic pressures above this point are similar to those in the aorta. The presence of SAM-septal contact at rest or with provocation will produce a pressure gradient of 30 mmHg or greater.</p><p>There are multiple morphologic alterations of the LVOT area and mitral valve that contribute to the development of SAM-septal contact, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Narrowed diameter of the LVOT due to increased septal wall thickness</p><p class="bulletIndent1"><span class="glyph">●</span>Apically positioned papillary muscles that tether the mitral valve plane toward the ventricular septum</p><p class="bulletIndent1"><span class="glyph">●</span>Elongated anterior leaflet of the mitral valve</p><p></p><p>As high-velocity blood is ejected from the LV during systole, the mitral valve is pulled or "dragged" toward the ventricular septum (Venturi effect), creating outflow tract obstruction [<a href="#rid1">1</a>]. SAM usually involves only the anterior mitral valve leaflet, but the posterior leaflet and chordal structures may also be involved. When SAM of the mitral valve occurs, a gap may be present between the anterior and posterior mitral leaflets, which often produces posteriorly directed mitral regurgitation (MR) and which may also contribute to symptoms. (See <a class="local">'Development of mitral regurgitation'</a> below and  <a class="medical medical_review" href="/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation", section on 'LVOT obstruction'</a>.)</p><p>A substantial body of echocardiographic, hemodynamic, and cineangiographic evidence in patients with a resting LVOT gradient &gt;50 mmHg associated with SAM and MR has yielded the following [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The magnitude of LVOT pressure gradient measured at cardiac catheterization correlates well with Doppler velocities and with the duration of SAM-septal contact. For this reason, there is usually no compelling rationale for patients to undergo catheterization to assess outflow tract gradients, unless the measurements on echocardiographic assessment are ambiguous. (See  <a class="medical medical_review" href="/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation", section on 'Diagnostic evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>LVOT obstruction can occur associated with any septal wall thickness. In patients with normal or mild increases in septal wall thickness, the mechanism for outflow obstruction is usually due to elongated anterior mitral valve leaflet. This is clinically relevant since those patients who are symptomatic despite drug therapy with elongated mitral valve leaflet should be considered for surgical myectomy with limited septal resection with mitral valve repair (ie, plication), rather than percutaneous approach with alcohol septal ablation [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/4920.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients with outflow tract obstruction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is often an area of scarring at the site of repetitive SAM mitral-septal contact (contact lesion).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although some patients with LVOT gradients of &gt;50 mmHg have mild or no symptoms, in most patients, the magnitude of the gradient relates to symptoms and exercise limitation, which provides the rationale for treatments aimed at gradient reduction. Factors that aggravate LVOT obstruction may increase or induce symptoms of exercise limitation, syncope, and/or ischemic chest pain [<a href="#rid3">3</a>]. Conversely, therapies that reduce LVOT obstruction alleviate symptoms.</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Development of mitral regurgitation</span><span class="headingEndMark"> — </span>In addition to producing subaortic obstruction, SAM of the mitral valve also results in varying degrees of posteriorly directed MR due to a gap between the mitral leaflets. There are several variables which influence MR, resulting in great interindividual differences in MR at comparable degrees of SAM of the mitral valve; nonetheless, there is a correlation between the severity of MR and the LVOT gradient.</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 23 patients with obstructive HCM undergoing surgery, differences in mitral valve leaflet length and mobility appeared to influence the extent of MR [<a href="#rid4">4</a>]. SAM produced greater MR if the posterior leaflet was limited (by its chordal and papillary muscle connections) in its ability to move anteriorly and participate in SAM and to coapt effectively (<a class="graphic graphic_figure graphicRef54090" href="/d/graphic/54090.html" rel="external">figure 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one study of 93 patients without independent mitral valve disease, the mean LVOT gradient in those with trivial, mild, moderate, and severe MR was 23, 44, 70, and 104 mmHg, respectively [<a href="#rid5">5</a>].</p><p></p><p>In contrast to posteriorly directed MR, the presence of a central or anteriorly directed MR jet suggests the presence of intrinsic mitral valve disease and should be evaluated further with transesophageal echocardiography, particularly if the patient is a candidate for invasive septal reduction therapy, since this may require repair of the mitral valve at the time the outflow tract gradient is relieved.</p><p class="headingAnchor" id="H175543177"><span class="h1">DYNAMIC NATURE OF LVOT OBSTRUCTION</span><span class="headingEndMark"> — </span>There can be significant variability in the degree of LVOT obstruction in HCM. LVOT obstruction at rest is a consistent finding in some patients with HCM (<a class="graphic graphic_waveform graphicRef65202" href="/d/graphic/65202.html" rel="external">waveform 1</a> and <a class="graphic graphic_waveform graphicRef66652" href="/d/graphic/66652.html" rel="external">waveform 2</a>) [<a href="#rid1">1</a>]. In others, there is no evidence of LV outflow obstruction at rest, but outflow tract obstruction which develops with certain provocative conditions (<a class="graphic graphic_waveform graphicRef65235" href="/d/graphic/65235.html" rel="external">waveform 3</a>).</p><p>A variety of maneuvers and medications can result in either induction/increase or reduction/elimination of LVOT obstruction.</p><p class="bulletIndent1"><span class="glyph">●</span>Inducing/increasing LVOT obstruction – LVOT obstruction can be induced or increased by maneuvers that reduce preload (chamber size), decrease afterload, or increase LV inotropy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Preload is reduced by dehydration, sudden adoption of the upright posture, the Valsalva maneuver, and certain medications (eg, diuretics, dihydropyridine calcium channel blockers, etc).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Conditions associated with increased inotropy include fever, exercise, <a class="drug drug_general" data-topicid="8578" href="/d/drug information/8578.html" rel="external">isoproterenol</a>/<a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> infusion, or postextrasystolic potentiation (ie, increased inotropy after an extrasystolic beat). The increased LVOT gradient and reduced aortic pulse pressure caused by postextrasystolic potentiation is known as the Brockenbrough sign. (See  <a class="medical medical_review" href="/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation", section on 'Cardiac catheterization'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reducing/eliminating LVOT obstruction – LVOT obstruction can be reduced or eliminated by maneuvers that increase chamber size or medications which reduce inotropy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Squatting or laying supine with legs elevated will increase venous return and preload, whereas isometric handgrip exercise will increase afterload; all of these maneuvers result in an increased LV cavity size and reduced LVOT obstruction.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Drugs that reduce inotropy (eg, beta blockers, nondihydropyridine calcium channel blockers [specifically <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a> and <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>], and <a class="drug drug_general" data-topicid="9378" href="/d/drug information/9378.html" rel="external">disopyramide</a>) also diminish obstruction.</p><p></p><p>Notably, LVOT gradients in HCM are dynamic, characterized by marked spontaneous changes under basal conditions, which can result in varying gradients from zero to very high values. LVOT gradients are also influenced by a variety of factors that alter LV contractility and loading, including exercise, level of hydration, ingestion of alcohol, or heavy meals (<a class="graphic graphic_waveform graphicRef65749" href="/d/graphic/65749.html" rel="external">waveform 4</a>) [<a href="#rid6">6-8</a>].</p><p class="headingAnchor" id="H1711150233"><span class="h1">HCM VARIANTS</span><span class="headingEndMark"> — </span>In addition to the classic description of HCM with or without LVOT obstruction, a variety of other HCM variants exist, some of which are managed quite differently than classic HCM.</p><p class="headingAnchor" id="H3228546507"><span class="h2">Midcavity obstructive HCM</span><span class="headingEndMark"> — </span>Midcavity (ie, midventricular) obstruction is an important morphologic variant of HCM, which arises from different anatomic and hemodynamic circumstances [<a href="#rid9">9,10</a>]. Perhaps the most common HCM morphology associated with midcavitary obstruction occurs due to the apposition of septum and lateral wall in the context of a small, hyperdynamic cavity. In these patients the intracavitary "gradient" does not usually produce clinically significant symptoms, although beta blockers appear to be the most reasonable therapy in symptomatic patients.</p><p>Midcavity obstruction in HCM can also be due to the systolic apposition of hypertrophied papillary muscle and lateral wall at the level of the mid-LV, producing two distinct LV chambers (ie, proximal and distal with an "hour glass" shape LV), and associated with an LV apical aneurysm of varying size [<a href="#rid10">10</a>]. This phenotypic subgroup of HCM patients is uncommon, presenting in approximately 2 percent of patients with HCM [<a href="#rid11">11</a>]. (See <a class="local">'Midcavity obstruction with LV apical aneurysm'</a> below.)</p><p>Another cause of midcavitary obstruction is anomalous insertion of the anterolateral papillary muscle directly into the anterior leaflet of the mitral valve (in the absence of chordae tendineae). In this morphologic abnormality, the anomalous papillary muscle is often apically displaced and along with the anterior leaflet makes contact with the septum at midsystole to produce midcavitary obstruction [<a href="#rid11">11,12</a>]. In this situation, patients may have limiting symptoms similar to patients with typical isolated LVOT obstruction. Clinical examination reveals the typical signs of dynamic obstructive HCM (eg, a systolic murmur that accentuates with exercise or a change to an upright posture). (See <a class="local">'Dynamic nature of LVOT obstruction'</a> above and  <a class="medical medical_review" href="/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation"</a> and  <a class="medical medical_review" href="/d/html/1078.html" rel="external">"Auscultation of cardiac murmurs in adults"</a> and  <a class="medical medical_review" href="/d/html/1080.html" rel="external">"Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds"</a> and <a class="local">'Midcavity obstruction with LV apical aneurysm'</a> below.)</p><p>The diagnosis of midcavity obstructive HCM can be made with echocardiography, left ventriculography, or cardiovascular magnetic resonance (CMR) [<a href="#rid13">13</a>]. Imaging in isolated midcavity HCM shows absence of systolic anterior motion of the mitral valve and a narrowed mid-LV cavity with or without an LV apical aneurysm. High Doppler velocities, indicating a midcavity gradient, are recorded at the level of the papillary muscle. Color Doppler demonstrates a mosaic pattern at this level, confirming that the level of obstruction is below the mitral valve leaflets. In some patients, the midcavity obstruction is associated with an apical LV aneurysm, which may be the site of origin of a rapid monomorphic ventricular tachycardia and clot formation (<a class="graphic graphic_diagnosticimage graphicRef59767" href="/d/graphic/59767.html" rel="external">image 1</a>).</p><p>Patients with HCM and midcavitary obstruction from anomalous papillary muscle insertion, with or without associated LVOT obstruction, and who have advanced HF symptoms refractory to atrioventricular (AV) nodal blocking agents (ie, beta blockers and nondihydropyridine calcium channel blockers), should be evaluated for invasive septal reduction therapy. In most cases, the identification of anomalous papillary muscle insertion sways the decision toward surgical myectomy rather than alcohol septal ablation, since only surgery can address the morphologic abnormality of midcavitary obstruction. In addition, advance knowledge of the anomalous papillary muscle insertion is crucial as knowing this information may change operative strategy to an extended myectomy and adjunctive papillary muscle shaving in order to provide the patient complete relief of outflow tract obstruction. (See  <a class="medical medical_review" href="/d/html/4920.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients with outflow tract obstruction"</a>.)</p><p class="headingAnchor" id="H2161960079"><span class="h2">Midcavity obstruction with LV apical aneurysm</span><span class="headingEndMark"> — </span>Some patients with HCM and midcavity obstruction develop thin-walled scarred LV apical aneurysms. These patients represent a different phenotype than apical HCM in which the apex is the primary site of LV hypertrophy. (See <a class="local">'Apical HCM'</a> below.)</p><p>Patients with HCM and LV apical aneurysms are at increased risk of ventricular arrhythmias (including sudden cardiac death [SCD]), thromboembolic events, and advanced HF. The junction of the thin-walled scarred apical aneurysm and the LV myocardium provides a nidus for ventricular tachyarrhythmias and thrombus formation. For this reason, patients with HCM and an apical aneurysm appear to be at increased risk for sudden death events and stroke. There is no evidence that these apical aneurysms rupture or expand in size over time. In addition, these patients can also experience limiting HF symptoms, although this is often a result of developing systolic dysfunction rather than a consequence of midcavitary obstruction. Rarely, patients with HCM and an apical aneurysm will also have coexistent subaortic obstruction due to SAM-septal contact; in such patients, the clinical examination will demonstrate typical signs of dynamic obstructive HCM (eg, a systolic murmur that accentuates with exercise or a change to upright posture).</p><p>The diagnosis of midcavity obstruction with apical aneurysm is typically made with echocardiography, left ventriculography, or CMR [<a href="#rid13">13,14</a>]. In one series, echocardiography detected an apical aneurysm in only 16 of 28 (57 percent) patients with apical aneurysm, but CMR detected the aneurysm in all 28 patients [<a href="#rid15">15</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In one series of 93 patients with HCM with apical aneurysm followed for a mean of four years, 20 experienced an SCD event rate of 4.7 percent per year and a nonfatal embolic event rate of 1.1 percent per year. HCM-related deaths and life-threatening events due to apical aneurysm occurred at a rate of 6.4 percent per year, which was three times greater than the rate in patients with HCM without aneurysms [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a recent series of 160 patients with HCM with apical aneurysm followed for a mean of six years, 9 percent experienced an SCD event (1.7 percent per year), and 24 percent of patients had stroke or thrombus identified in the apical aneurysm. When compared with patients who had an aneurysm &lt;2 cm, patients with an aneurysm ≥2 cm had a higher risk of SCD and stroke events [<a href="#rid17">17</a>].</p><p></p><p>For these reasons, identification of this unique HCM phenotype with LV apical aneurysm should prompt consideration for primary prevention implantable cardioverter-defibrillator (ICD) and anticoagulation for stroke prophylaxis. Catheter ablation has been used successfully to mitigate or eliminate ventricular tachycardia in patients with HCM and an apical aneurysm who have experienced multiple episodes of sustained ventricular arrhythmias [<a href="#rid16">16,18</a>]. Ultimately, management recommendations should be carried out implementing a shared decision-making strategy with the patient and the managing cardiologist, with an understanding of the inherent limitations of risk stratification applied to an uncommon cohort of patients. (See  <a class="medical medical_review" href="/d/html/4952.html" rel="external">"Hypertrophic cardiomyopathy: Risk stratification for sudden cardiac death", section on 'Established major risk markers'</a>.)</p><p class="headingAnchor" id="H3851897598"><span class="h2">Apical HCM</span><span class="headingEndMark"> — </span>Apical HCM is another uncommon morphologic variant of HCM in which the hypertrophy of the myocardium predominantly involves the apex of the LV [<a href="#rid19">19,20</a>]. The majority of these patients do not have subaortic LVOT obstruction but may have midcavity obstruction [<a href="#rid15">15,20</a>]. (See <a class="local">'Midcavity obstructive HCM'</a> above.)</p><p>The prevalence of apical HCM has been difficult to quantify. Some data suggest significant regional variation, though the data are not compelling [<a href="#rid15">15,21-25</a>].</p><p>Most patients with apical HCM present with no or mild symptoms, although presentation with angina, HF, myocardial infarction, atrial fibrillation (AF), or ventricular fibrillation has been reported [<a href="#rid15">15,20</a>]. AF has been reported in 12 to 25 percent of patients with apical HCM, similar to the rate in general cohorts of patients with HCM [<a href="#rid20">20,26</a>]. Symptoms are often mild, but a minority of patients have refractory symptoms of dyspnea, angina, and presyncope or syncope due to diastolic dysfunction and low cardiac output. Apical myectomy has been reported as a potential option in select patients with low stroke volume (low output HF) due to very small LV cavity from extensive distal hypertrophy. (See  <a class="medical medical_review" href="/d/html/4920.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients with outflow tract obstruction"</a>.)</p><p>Typical features of apical HCM include [<a href="#rid21">21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Audible or palpable "fourth heart sound," reflecting impaired LV relaxation</p><p class="bulletIndent1"><span class="glyph">●</span>"Giant" negative T waves on electrocardiogram, particularly in the left precordial leads</p><p class="bulletIndent1"><span class="glyph">●</span>"Spade-like" configuration of the LV cavity at end-diastole on imaging</p><p class="bulletIndent1"><span class="glyph">●</span>Associated apical wall motion abnormalities which may include hypokinesis and aneurysm formation [<a href="#rid20">20</a>]</p><p></p><p>The diagnosis of apical HCM can be made with echocardiography, left ventriculography, computed tomography, or most accurately with CMR [<a href="#rid15">15,27,28</a>]. Multimodality imaging with several of the available techniques can provide the most accurate assessment of the phenotypic anatomy [<a href="#rid29">29</a>].</p><p>The approach to the management of apical HCM is the same as for most patients with HCM. Symptomatic patients are initially treated with medical therapy; however, since nearly all patients with apical HCM do not have evidence of LVOT or midcavity obstruction, septal reduction therapy is almost never an option in those patients [<a href="#rid21">21</a>]. Risk stratification for ventricular tachyarrhythmias and SCD is the same as for other patients with HCM, but apical HCM is typically associated with a low risk and almost never requires ICD placement for primary prevention [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/4920.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients with outflow tract obstruction"</a>.)</p><p>The apical variant has a better mortality prognosis than other forms of HCM but is still associated with a relatively high rate of important cardiac events. In one series of 105 patients with apical HCM (mean age 41 years) followed for a mean of 13.6 years at a referral center in Canada, the total cardiovascular mortality rate was 1.9 and overall estimated survival was 95 percent at 15 years [<a href="#rid20">20</a>]. However, 30 percent of patients experienced a serious cardiac complication, most commonly AF (12 percent) or a myocardial infarction (10 percent). In a different cohort of 306 Korean patients with apical HCM, AF was seen in 77 patients (25 percent) [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/d/html/4916.html" rel="external">"Hypertrophic cardiomyopathy: Natural history and prognosis"</a>.)</p><p class="headingAnchor" id="H3606988695"><span class="h2">Right ventricular obstruction</span><span class="headingEndMark"> — </span>A very small number of HCM patients demonstrate obstruction to flow on the right ventricular (RV) outflow tract. This is usually a result of midsystolic contact of prominent right ventricular muscle bundles located in the RV outflow tract region (<a class="graphic graphic_figure graphicRef58156" href="/d/graphic/58156.html" rel="external">figure 1</a>). RV obstruction in HCM is very uncommon but can be identified using echocardiography with 2D and Doppler pulse wave through the RV outflow tract. If present, RV obstruction can be a cause of symptoms such as exertional dyspnea similar to left-sided obstruction. The approach to treatment is similar to the standard approach to treatment for patients with HCM and LVOT obstruction. Patients who remain symptomatic after a trial of medical therapy with AV nodal blocking agents can be considered for surgical intervention to relieve right-sided obstruction, usually by resection of accessory RV muscle bundles in the outflow tract area [<a href="#rid31">31,32</a>]. (See  <a class="medical medical_review" href="/d/html/4950.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients without outflow tract obstruction"</a> and  <a class="medical medical_review" href="/d/html/4920.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients with outflow tract obstruction"</a>.)</p><p class="headingAnchor" id="H2424449019"><span class="h2">Obstructive HCM in older adults</span><span class="headingEndMark"> — </span>Although the majority of patients with HCM patients are diagnosed at a relatively young age (average 44 years old), HCM can also be diagnosed initially in patients of advanced age. Regardless of the age at diagnosis, patients with increased LV wall thickness and LVOT obstruction may develop symptoms. The approach to the treatment of symptomatic LVOT obstruction is the same regardless of age (ie, initial medical therapy, followed by septal reduction therapy if symptoms persist), although older patients are more likely to have comorbidities (eg, coronary heart disease, aortic stenosis, etc) that may also require treatment. (See  <a class="medical medical_review" href="/d/html/4950.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients without outflow tract obstruction"</a> and  <a class="medical medical_review" href="/d/html/4920.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients with outflow tract obstruction"</a>.)</p><p>In data from the Framingham Heart Study, among 1862 unrelated individuals of advanced age (mean 60 years old) who did not have hypertension or aortic valve disease, 3 percent had unexplained increase in LV wall thickness [<a href="#rid33">33</a>]. Sarcomeric contractile protein gene mutations were found in only 18 percent of these individuals. In another study of 31 individuals with late-onset HCM, who first developed symptoms at an average age of 60 years, mutations in cardiac myosin binding protein-C, troponin I, and alpha cardiac myosin heavy chain genes caused onset of HCM later in life, in contrast to familial early-onset HCM which results more commonly from defects in cardiac beta-myosin heavy chain, cardiac troponin T, and alpha tropomyosin genes [<a href="#rid34">34</a>]. In addition, the likelihood of identifying a mutation may be lower in late-onset HCM than in earlier onset HCM [<a href="#rid35">35,36</a>]. (See  <a class="medical medical_review" href="/d/html/4916.html" rel="external">"Hypertrophic cardiomyopathy: Natural history and prognosis", section on 'Late onset disease'</a>.)</p><p>The following clinical features have been noted [<a href="#rid37">37-40</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In comparison to younger patients, individuals with late onset disease tend to have milder hypertrophy that is localized to the anterior interventricular septum, and an ovoid or ellipsoid (rather than crescentic) LV cavity. Hypertension is more frequent than in younger subjects, but its role in triggering the development of hypertrophy is unclear.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systolic anterior motion of the mitral valve and LVOT gradients in older patients tend to be associated with very narrow LVOTs, anterior displacement of the entire mitral valve apparatus, and a larger area of contact between the mitral valve leaflet and the septum than in younger subjects with HCM.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obstructive HCM in older adults is sometimes complicated by aortic sclerosis or stenosis. Severe aortic stenosis may mask underlying LV obstruction. As a result, echocardiography may show calcific aortic stenosis in association with a markedly hypertrophied and asymmetric LV. (See  <a class="medical medical_review" href="/d/html/8123.html" rel="external">"Aortic valve sclerosis and pathogenesis of calcific aortic stenosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A characteristic feature of some cases of late onset disease is increased angulation of the aorta with respect to the long axis of the LV. This may reflect age-related "shrinkage" of the heart resulting in an upper septal bulge (sigmoid septum) and narrowing of the LVOT. These changes occur in older adults with and without HCM. This sigmoid septal morphology is less commonly associated with a mutation than other HCM morphologic variants.</p><p></p><p>The clinical outcome of patients diagnosed with HCM at advanced age appears to be similar to outcomes in the general population. In a study of 428 older patients with HCM (presenting for clinical evaluation at ≥60 years of age) who were followed for close to five years, the risk for disease-related morbidity and mortality, including sudden death, even with conventional risk factors was very low. In this population, non-HCM comorbidities appear to have a greater impact on survival [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/d/html/4916.html" rel="external">"Hypertrophic cardiomyopathy: Natural history and prognosis"</a>.)</p><p class="headingAnchor" id="H3954655540"><span class="h3">Sigmoid septal morphology</span><span class="headingEndMark"> — </span>A sigmoidal configuration to the basal septum is observed with increased frequency in older individuals and may occur as part of the cardiac remodeling associated with aging [<a href="#rid42">42</a>]. However, a sigmoid shaped septum is still compatible with a diagnosis of HCM but only if the basal septal wall thickness measurement is increased. [<a href="#rid36">36</a>]. Additionally, the presence of systolic anterior motion with septal contact resulting in an LVOT gradient (ie, subaortic obstruction) strongly suggests a diagnosis of HCM in patients with is isolated sigmoid septal hypertrophy [<a href="#rid42">42</a>].</p><p>Among patients with HCM, this morphologic subtype appears to be less commonly associated with a mutation than other morphologic variants. Among 382 unrelated patients with HCM, a sigmoid septum was observed in 67 percent of the 126 patients diagnosed at or after 50 years of age as compared with 38 percent of younger patients. Only 23 percent of older patients had an identifiable mutation as compared with 44 percent of younger patients. Among 181 patients with a sigmoid septum, only 8 percent were genotype positive as compared with 79 percent of 131 patients with reverse curvature HCM.</p><p class="headingAnchor" id="H101311638"><span class="h2">End-stage hypertrophic cardiomyopathy</span><span class="headingEndMark"> — </span>Progressive LV wall thinning occurs in approximately 5 to 15 percent of patients with HCM [<a href="#rid43">43-46</a>]. This is associated with deterioration in LV diastolic and systolic function, which is initially presaged by loss of long-axis contractile function prior to more generalized decrease in LV function and dilation. When wall thinning is marked, it is usually associated with replacement fibrosis and a significant decrease in systolic function. This stage has been termed "end-stage" or "burned out" HCM and is seen in up to 5 percent of patients from large cohorts (<a class="graphic graphic_figure graphicRef81390" href="/d/graphic/81390.html" rel="external">figure 3</a>). End-stage HCM patients are at increased risk for HF progression and sudden death risk, raising important management considerations in these patients including close longitudinal follow-up with earlier consideration to advanced HF therapies and ICD for primary prevention. (See  <a class="medical medical_review" href="/d/html/4916.html" rel="external">"Hypertrophic cardiomyopathy: Natural history and prognosis", section on 'HCM with LV systolic dysfunction (ejection fraction &lt;50 percent)'</a>.)</p><p class="headingAnchor" id="H1393083"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/15753.html" rel="external">"Patient education: Hypertrophic cardiomyopathy in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/3445.html" rel="external">"Patient education: Hypertrophic cardiomyopathy (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H14370275"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence of outflow tract obstruction</strong> – Left ventricular outflow tract (LVOT) obstruction (≥30 mmHg) at rest is present in up to 30 percent of patients with hypertrophic cardiomyopathy (HCM), while an additional 30 percent have no evidence of LVOT obstruction at rest but develop outflow tract obstruction with provocation. LVOT obstruction is a dynamic process and can be induced or increased by maneuvers that reduce preload (chamber size), decrease afterload, or increase LV inotropy. (See <a class="local">'Introduction'</a> above and <a class="local">'Dynamic nature of LVOT obstruction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Typical mechanism of outflow tract obstruction</strong> – Subaortic obstruction in HCM is due to systolic anterior motion (SAM) of the mitral valve with ventricular-septal contact occurring in midsystole. The high velocity of blood flow out of the LV during systole pulls the mitral valve leaflet toward the ventricular septum (Venturi effect), creating mechanical impedance to blood flow and a pressure gradient between the LV and aorta as well as posteriorly directed mild to moderate mitral regurgitation (MR). A combination of morphologic factors contribute to SAM-septal contact, including narrow outflow tract area, abnormal positioning of the mitral valve plane toward the septum, and elongated anterior mitral valve leaflet. (See <a class="local">'Mechanism of LVOT obstruction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Morphologic variants</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Midcavity obstruction</strong> – Midcavity (ie, midventricular) obstruction is an uncommon morphologic variant of HCM, typically due to the systolic apposition of hypertrophied papillary muscle and lateral wall at the level of the mid-LV, in the setting of a small cavity and hyperdynamic function. Some patients develop midcavity obstruction due to anomalous papillary muscle insertion directly into the mitral valve, which will make contact with septum and lateral wall during midsystole. Patients with HCM and midcavity obstruction due to anomalous papillary muscle insertion who develop medically refractory heart failure (HF) symptoms should be evaluated for myectomy rather than alcohol septal ablation, since only surgery can address this unique morphologic issue. (See <a class="local">'Midcavity obstructive HCM'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Apical aneurysm</strong> –<strong> </strong>Some patients with HCM and midcavity obstruction develop thin-walled scarred LV apical aneurysms, a high-risk phenotype, associated with increased risk for sudden death events, thromboembolic events, and advanced HF symptoms. Identification of this unique HCM phenotype with LV apical aneurysm should prompt consideration for primary prevention implantable cardioverter-defibrillator (ICD), anticoagulation for stroke prophylaxis, and, in select patients, catheter ablation to treat recurrent sustained episodes of ventricular tachycardia. (See <a class="local">'Midcavity obstruction with LV apical aneurysm'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Apical hypertrophy</strong> – Apical HCM is another uncommon morphologic variant of HCM in which the hypertrophy of the myocardium predominantly involves the apex of the LV. These patients do not have subaortic LVOT obstruction but may have midcavity obstruction from apposition of septum and lateral wall in the setting of a small hyperdynamic cavity. The approach to the management of apical HCM is the same as for most patients with HCM. (See <a class="local">'Apical HCM'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypertrophic cardiomyopathy in older adults</strong> – Although the majority of HCM patients are diagnosed at a relatively young age (average 44 years old), HCM can also be diagnosed initially in patients of advanced age. Regardless of the age at diagnosis, patients with increase LV wall thickness and LVOT obstruction may develop symptoms. The approach to the treatment of symptomatic LVOT obstruction is the same regardless of age (ie, initial medical therapy, followed by septal reduction therapy if symptoms persist), although older patients are more likely to have comorbidities (eg, coronary heart disease, aortic stenosis, etc) that may also require treatment. (See <a class="local">'Obstructive HCM in older adults'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>End-stage hypertrophic cardiomyopathy</strong> – End-stage HCM is characterized by thinning of the ventricular walls and deterioration in LV diastolic and systolic function. (See <a class="local">'End-stage hypertrophic cardiomyopathy'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Veselka J, Anavekar NS, Charron P. Hypertrophic obstructive cardiomyopathy. Lancet 2017; 389:1253.</a></li><li><a class="nounderline abstract_t">Rowin EJ, Maron BJ, Chokshi A, et al. Clinical Spectrum and Management Implications of Left Ventricular Outflow Obstruction With Mild Ventricular Septal Thickness in Hypertrophic Cardiomyopathy. Am J Cardiol 2018; 122:1409.</a></li><li><a class="nounderline abstract_t">Maron BJ, Epstein SE, Roberts WC. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am J Cardiol 1979; 43:1086.</a></li><li><a class="nounderline abstract_t">Schwammenthal E, Nakatani S, He S, et al. Mechanism of mitral regurgitation in hypertrophic cardiomyopathy: mismatch of posterior to anterior leaflet length and mobility. Circulation 1998; 98:856.</a></li><li><a class="nounderline abstract_t">Yu EH, Omran AS, Wigle ED, et al. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. J Am Coll Cardiol 2000; 36:2219.</a></li><li><a class="nounderline abstract_t">Kizilbash AM, Heinle SK, Grayburn PA. Spontaneous variability of left ventricular outflow tract gradient in hypertrophic obstructive cardiomyopathy. Circulation 1998; 97:461.</a></li><li><a class="nounderline abstract_t">Geske JB, Sorajja P, Ommen SR, Nishimura RA. Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy. JACC Cardiovasc Interv 2011; 4:704.</a></li><li><a class="nounderline abstract_t">Feiner E, Arabadjian M, Winson G, et al. Post-prandial upright exercise echocardiography in hypertrophic cardiomyopathy. J Am Coll Cardiol 2013; 61:2487.</a></li><li><a class="nounderline abstract_t">Fighali S, Krajcer Z, Edelman S, Leachman RD. Progression of hypertrophic cardiomyopathy into a hypokinetic left ventricle: higher incidence in patients with midventricular obstruction. J Am Coll Cardiol 1987; 9:288.</a></li><li><a class="nounderline abstract_t">Silbiger JJ. Abnormalities of the Mitral Apparatus in Hypertrophic Cardiomyopathy: Echocardiographic, Pathophysiologic, and Surgical Insights. J Am Soc Echocardiogr 2016; 29:622.</a></li><li><a class="nounderline abstract_t">Rowin EJ, Maron BJ, Lesser JR, et al. Papillary muscle insertion directly into the anterior mitral leaflet in hypertrophic cardiomyopathy, its identification and cause of outflow obstruction by cardiac magnetic resonance imaging, and its surgical management. Am J Cardiol 2013; 111:1677.</a></li><li><a class="nounderline abstract_t">Klues HG, Roberts WC, Maron BJ. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significance in producing left ventricular outflow obstruction. Circulation 1991; 84:1188.</a></li><li><a class="nounderline abstract_t">Maron BJ, Maron MS. The Remarkable 50 Years of Imaging in HCM and How it Has Changed Diagnosis and Management: From M-Mode Echocardiography to CMR. JACC Cardiovasc Imaging 2016; 9:858.</a></li><li><a class="nounderline abstract_t">Tower-Rader A, Kramer CM, Neubauer S, et al. Multimodality Imaging in Hypertrophic Cardiomyopathy for Risk Stratification. Circ Cardiovasc Imaging 2020; 13:e009026.</a></li><li><a class="nounderline abstract_t">Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation 2008; 118:1541.</a></li><li><a class="nounderline abstract_t">Rowin EJ, Maron BJ, Haas TS, et al. Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. J Am Coll Cardiol 2017; 69:761.</a></li><li><a class="nounderline abstract_t">Lee DZJ, Montazeri M, Bataiosu R, et al. Clinical Characteristics and Prognostic Importance of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy. JACC Cardiovasc Imaging 2022; 15:1696.</a></li><li><a class="nounderline abstract_t">Igarashi M, Nogami A, Kurosaki K, et al. Radiofrequency Catheter Ablation of Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy and Apical Aneurysm. JACC Clin Electrophysiol 2018; 4:339.</a></li><li><a class="nounderline abstract_t">Sakamoto T. Apical hypertrophic cardiomyopathy (apical hypertrophy): an overview. J Cardiol 2001; 37 Suppl 1:161.</a></li><li><a class="nounderline abstract_t">Eriksson MJ, Sonnenberg B, Woo A, et al. Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39:638.</a></li><li><a class="nounderline abstract_t">Hughes RK, Knott KD, Malcolmson J, et al. Apical Hypertrophic Cardiomyopathy: The Variant Less Known. J Am Heart Assoc 2020; 9:e015294.</a></li><li><a class="nounderline abstract_t">Ho HH, Lee KL, Lau CP, Tse HF. Clinical characteristics of and long-term outcome in Chinese patients with hypertrophic cardiomyopathy. Am J Med 2004; 116:19.</a></li><li><a class="nounderline abstract_t">Kitaoka H, Doi Y, Casey SA, et al. Comparison of prevalence of apical hypertrophic cardiomyopathy in Japan and the United States. Am J Cardiol 2003; 92:1183.</a></li><li><a class="nounderline abstract_t">Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995; 26:1699.</a></li><li><a class="nounderline abstract_t">Chikamori T, Doi YL, Akizawa M, et al. Comparison of clinical, morphological, and prognostic features in hypertrophic cardiomyopathy between Japanese and western patients. Clin Cardiol 1992; 15:833.</a></li><li><a class="nounderline abstract_t">Lee SE, Park JK, Uhm JS, et al. Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy. Heart 2017; 103:1496.</a></li><li><a class="nounderline abstract_t">Pons-Lladó G, Carreras F, Borrás X, et al. Comparison of morphologic assessment of hypertrophic cardiomyopathy by magnetic resonance versus echocardiographic imaging. Am J Cardiol 1997; 79:1651.</a></li><li><a class="nounderline abstract_t">Moon JC, Fisher NG, McKenna WJ, Pennell DJ. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart 2004; 90:645.</a></li><li><a class="nounderline abstract_t">Hughes RK, Knott KD, Malcolmson J, et al. Advanced Imaging Insights in Apical Hypertrophic Cardiomyopathy. JACC Cardiovasc Imaging 2020; 13:624.</a></li><li><a class="nounderline abstract_t">Itzhaki Ben Zadok O, Hasdai D, Witberg G, et al. Calculated Risk for Sudden Cardiac Death in Patients with Apical Versus Nonobstructive Nonapical Hypertrophic Cardiomyopathy. Am J Cardiol 2018; 122:1551.</a></li><li><a class="nounderline abstract_t">Malik R, Maron MS, Rastegar H, Pandian NG. Hypertrophic cardiomyopathy with right ventricular outflow tract and left ventricular intracavitary obstruction. Echocardiography 2014; 31:682.</a></li><li><a class="nounderline abstract_t">Mozaffarian D, Caldwell JH. Right ventricular involvement in hypertrophic cardiomyopathy: a case report and literature review. Clin Cardiol 2001; 24:2.</a></li><li><a class="nounderline abstract_t">Morita H, Larson MG, Barr SC, et al. Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham Heart Study. Circulation 2006; 113:2697.</a></li><li><a class="nounderline abstract_t">Niimura H, Patton KK, McKenna WJ, et al. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation 2002; 105:446.</a></li><li><a class="nounderline abstract_t">Van Driest SL, Ommen SR, Tajik AJ, et al. Yield of genetic testing in hypertrophic cardiomyopathy. Mayo Clin Proc 2005; 80:739.</a></li><li><a class="nounderline abstract_t">Binder J, Ommen SR, Gersh BJ, et al. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. Mayo Clin Proc 2006; 81:459.</a></li><li><a class="nounderline abstract_t">Lewis JF, Maron BJ. Elderly patients with hypertrophic cardiomyopathy: a subset with distinctive left ventricular morphology and progressive clinical course late in life. J Am Coll Cardiol 1989; 13:36.</a></li><li><a class="nounderline abstract_t">Fay WP, Taliercio CP, Ilstrup DM, et al. Natural history of hypertrophic cardiomyopathy in the elderly. J Am Coll Cardiol 1990; 16:821.</a></li><li><a class="nounderline abstract_t">Chikamori T, Doi YL, Yonezawa Y, et al. Comparison of clinical features in patients greater than or equal to 60 years of age to those less than or equal to 40 years of age with hypertrophic cardiomyopathy. Am J Cardiol 1990; 66:875.</a></li><li><a class="nounderline abstract_t">Lever HM, Karam RF, Currie PJ, Healy BP. Hypertrophic cardiomyopathy in the elderly. Distinctions from the young based on cardiac shape. Circulation 1989; 79:580.</a></li><li><a class="nounderline abstract_t">Maron BJ, Rowin EJ, Casey SA, et al. Risk stratification and outcome of patients with hypertrophic cardiomyopathy &gt;=60 years of age. Circulation 2013; 127:585.</a></li><li><a class="nounderline abstract_t">Canepa M, Pozios I, Vianello PF, et al. Distinguishing ventricular septal bulge versus hypertrophic cardiomyopathy in the elderly. Heart 2016; 102:1087.</a></li><li><a class="nounderline abstract_t">Thaman R, Gimeno JR, Reith S, et al. Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy. J Am Coll Cardiol 2004; 44:398.</a></li><li><a class="nounderline abstract_t">Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006; 114:216.</a></li><li><a class="nounderline abstract_t">Marstrand P, Han L, Day SM, et al. Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry. Circulation 2020; 141:1371.</a></li><li><a class="nounderline abstract_t">Rowin EJ, Maron BJ, Carrick RT, et al. Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction. J Am Coll Cardiol 2020; 75:3033.</a></li></ol></div><div id="topicVersionRevision">Topic 4947 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27912983" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hypertrophic obstructive cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30107902" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical Spectrum and Management Implications of Left Ventricular Outflow Obstruction With Mild Ventricular Septal Thickness in Hypertrophic Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/571670" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9738640" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mechanism of mitral regurgitation in hypertrophic cardiomyopathy: mismatch of posterior to anterior leaflet length and mobility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11127464" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9490241" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Spontaneous variability of left ventricular outflow tract gradient in hypertrophic obstructive cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21700258" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23602772" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Post-prandial upright exercise echocardiography in hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3805517" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Progression of hypertrophic cardiomyopathy into a hypokinetic left ventricle: higher incidence in patients with midventricular obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27146120" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Abnormalities of the Mitral Apparatus in Hypertrophic Cardiomyopathy: Echocardiographic, Pathophysiologic, and Surgical Insights.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23499271" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Papillary muscle insertion directly into the anterior mitral leaflet in hypertrophic cardiomyopathy, its identification and cause of outflow obstruction by cardiac magnetic resonance imaging, and its surgical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1884449" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significance in producing left ventricular outflow obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27388665" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The Remarkable 50 Years of Imaging in HCM and How it Has Changed Diagnosis and Management: From M-Mode Echocardiography to CMR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32063056" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Multimodality Imaging in Hypertrophic Cardiomyopathy for Risk Stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18809796" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28209216" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36202449" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical Characteristics and Prognostic Importance of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30089559" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Radiofrequency Catheter Ablation of Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy and Apical Aneurysm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11433822" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Apical hypertrophic cardiomyopathy (apical hypertrophy): an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11849863" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Long-term outcome in patients with apical hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32106746" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Apical Hypertrophic Cardiomyopathy: The Variant Less Known.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14706661" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical characteristics of and long-term outcome in Chinese patients with hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14609593" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Comparison of prevalence of apical hypertrophic cardiomyopathy in Japan and the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7594106" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10969627" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Comparison of clinical, morphological, and prognostic features in hypertrophic cardiomyopathy between Japanese and western patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28428444" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9202357" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Comparison of morphologic assessment of hypertrophic cardiomyopathy by magnetic resonance versus echocardiographic imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15145868" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31734201" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Advanced Imaging Insights in Apical Hypertrophic Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30197054" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Calculated Risk for Sudden Cardiac Death in Patients with Apical Versus Nonobstructive Nonapical Hypertrophic Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24649889" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hypertrophic cardiomyopathy with right ventricular outflow tract and left ventricular intracavitary obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11195601" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Right ventricular involvement in hypertrophic cardiomyopathy: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16754800" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11815426" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15945527" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Yield of genetic testing in hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16610565" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2909578" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Elderly patients with hypertrophic cardiomyopathy: a subset with distinctive left ventricular morphology and progressive clinical course late in life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2212364" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Natural history of hypertrophic cardiomyopathy in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2220593" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comparison of clinical features in patients greater than or equal to 60 years of age to those less than or equal to 40 years of age with hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2917389" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hypertrophic cardiomyopathy in the elderly. Distinctions from the young based on cardiac shape.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23275385" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Risk stratification and outcome of patients with hypertrophic cardiomyopathy&gt;=60 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27122487" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Distinguishing ventricular septal bulge versus hypertrophic cardiomyopathy in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15261938" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16831987" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32228044" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32553256" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
